Principal Investigator Substitution Sample Clauses

Principal Investigator Substitution. If, for any reason, Principal Investigator is unwilling or unable to continue to serve as Principal Investigator for the Study, Institution shall provide prompt written notice thereof to Sponsor. Institution shall consult with Sponsor regarding the appointment of a replacement principal investigator. Any replacement of Principal Investigator will be subject to Sponsor’s prior written approval and he/she must agree in writing to be bound by the terms of this Agreement. If Sponsor does not approve of the proposed replacement, all further enrollment of subjects at the Institution for this Study will cease immediately and, without limitation of any other rights or remedies that Sponsor may have hereunder or as a matter of law, Sponsor may elect to immediately terminate this Agreement, upon written notice to Institution. Institution may not replace Principal Investigator or substantially reduce his/her role in the Study without Sponsor’s prior written consent. 1.3.
Sample 1
AutoNDA by SimpleDocs
Principal Investigator Substitution. If, for any reason, Principal Investigator is unwilling or unable to continue to serve as principal investigator for the Trial, Institution or Principal Investigator shall provide prompt written notice thereof to CRO. Institution shall consult with CRO regarding the appointment of a replacement principal investigator. Any replacement Principal Investigator will be subject to CRO’s prior jen „subjekty klinického hodnocení“). Zadavatel chce zapojit zdravotnické zařízení, pod vedením hlavního zkoušejícího, do provádění klinického hodnocení, a zdravotnické zařízení chce takové zapojení přijmout, v souladu s podmínkami uvedenými v této smlouvě. PROTO NYNÍ, s ohledem na výše uvedená východiska, vzájemné závazky a dohody uvedené v této smlouvě, a výměnou za úplatu, jejíž přijetí a dostatečnost tímto strany potvrzují, se smluvní strany dohodly takto:
Sample 1
Principal Investigator Substitution. If, for any reason, Principal Investigator is unwilling or unable to continue to serve as principal investigator for the Trialy, Institution or Principal Investigator shall 1.3 Náhrada hlavného skúšajúceho. Ak z akéhokoľvek dôvodu hlavný skúšajúci nie je ochotný alebo schopný naďalej vykonávať funkciu hlavného skúšajúceho v skúšaní, zdravotnícke zariadenie alebo hlavný provide prompt written notice thereof to Syneos Health. Institution shall consult with Syneos Health regarding the appointment of a replacement principal investigator. Any replacement Principal Investigator will be subject to Syneos Health’s prior written approval and he/she must agree in writing to be bound by the terms of this Agreement. If Sponor does not approve of the proposed replacement, all further enrollment of subjects at the Institution for this Trial will cease immediately and, without limitation of any other rights or remedies that Syneos Health and Sponsor may have hereunder or as a matter of law, Syneos Health may elect to immediately terminate this Agreement, upon written notice to Institution on behalf of Sponsor. Institution may not replace Principal Investigator or substantially reduce his/her role in the Trial without Syneos Health’s prior written consent on behalf of Sponsor. skúšajúci okamžite zašlú písomný oznam spoločnosti Syneos Health. Zdravotnícke zariadenie sa poradí so spoločnosťou Syneos Health ohľadom vymenovania náhradného hlavného skúšajúceho. Akýkoľvek náhradný hlavný skúšajúci bude podliehať predchádzajúcemu písomnému schváleniu spoločnosťou Syneos Health a musí písomne vyjadriť záväzok, že bude viazaný podmienkami tejto zmluvy. Ak zadávateľ neschváli navrhovaného náhradníka, všetko ďalšie zaraďovanie účastníkov v zdravotníckom zariadení do tohto skúšania sa okamžite zastaví, a bez obmedzenia akýchkoľvek iných práv alebo náprav, ktoré tu spoločnosť Syneos Health a zadávateľ môžu mať podľa zákona, spoločnosť Syneos Health sa môže rozhodnúť okamžite ukončiť túto zmluvu písomným oznamom zdravotníckemu zariadeniu v mene zadávateľa. Zdravotnícke zariadenie nesmie nahradiť hlavného skúšajúceho alebo významne obmedziť jeho rolu v skúšaní bez predchádzajúceho písomného súhlasu spoločnosti Syneos Health v mene zadávateľa.
Sample 1
Principal Investigator Substitution. If, for any reason, Principal Investigator is unwilling or unable to continue to serve as principal investigator for the Trial, Institution shall provide prompt written notice thereof to CRO. Institution shall consult with CRO regarding the appointment of a replacement principal investigator. Any replacement Principal Investigator will be subject to CRO’s prior written approval and he/she must agree in writing to be bound by the terms of this Agreement. If Sponsor does not approve of the proposed replacement, all further enrollment of subjects at the Institution for this Trial will cease immediately and, without limitation of any other rights or remedies that CRO and Sponsor may have hereunder or as a matter of law, CRO may elect to immediately terminate this Agreement, upon written notice to Institution on behalf of Sponsor. Institution may not replace Principal Investigator or substantially reduce his/her role in the Trial without CRO’s prior written consent on behalf of Sponsor. jim byl delegován a zdokumentován. Zdravotnické zařízení, prostřednictvím hlavního zkoušejícího, může delegovat povinnosti a odpovědnost na personál zdravotnického zařízení pouze v rozsahu přípustném platnými právními předpisy (definovanými níže), a pouze pokud splňuje požadavky uvedené v této smlouvě. 1.3
Sample 1

Related to Principal Investigator Substitution

  • Principal Investigator The Research Project will be supervised by _____________ (Principal Investigator). If for any reason this individual is unable to continue to serve as principal investigator and a successor acceptable to both the University and the Sponsor is not available, this Agreement shall be terminated as provided in Article 6.

  • PRODUCT SUBSTITUTION In the event a specified manufacturer’s Product listed in the Contract becomes unavailable or cannot be supplied by the Contractor for any reason (except as provided for in the Savings/Force Majeure Clause) a Product deemed in writing by the Commissioner to be equal to or better than the specified Product must be substituted by the Contractor at no additional cost or expense to the Authorized User. Unless otherwise specified, any substitution of Product prior to the Commissioner’s written approval may be cause for cancellation of Contract.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Third Party Components The Products and Services may contain third party components (including open source software) subject to separate license agreements. To the limited extent a third party license expressly supersedes this XXXX, such third party license governs Customer’s use of that third party component.

Time is Money Join Law Insider Premium to draft better contracts faster.